About Us

The AI Drug Discovery Laboratory, under the direction of Professor Sang-Hyun Min, is dedicated to pioneering the identification and validation of novel anticancer targets and advancing small-molecule therapeutics via state-of-the-art AI-driven approaches. With a particular focus on cancer stem cells and organoid models, our research spans the forefront of target-based synthetic drug discovery across diseases such as cancer, osteoporosis, obesity, and diabetes. Furthermore, we leverage patient-derived induced pluripotent stem cells (iPSCs) in phenotype-driven drug screening, embracing innovative strategies for drug repositioning and precision medicine.